Discovery and validation of urinary biomarkers for detection of renal cell carcinoma

Maria Frantzi, Jochen Metzger, Rosamonde E Banks, Holger Husi, Julie Klein, Mohammed Dakna, William Mullen, Jonathan J Cartledge, Joost P Schanstra, Korbinian Brand, Markus A Kuczyk, Harald Mischak, Antonia Vlahou, Dan Theodorescu, Axel S Merseburger

Research output: Contribution to journalArticle

32 Citations (Scopus)


Clear cell renal cell carcinoma (RCC) has the highest incidence among the renal malignancies, often presenting non-specific or no symptoms at all. Moreover, with no diagnostic marker being available so far, almost 30% of the patients are diagnosed with metastatic disease and 30-40% of the patients initially diagnosed with localized tumor relapse. These facts introduce the clinical need of early diagnosis. This study is focused on the investigation of a marker model based on urinary peptides, as a tool for the detection of RCC in selected patients at risk. Upon evaluation of the marker model in an independent blinded set of 76 samples, 80% sensitivity and 87% specificity were reported. An additional dataset of 1077 samples was subsequently employed for further evaluation of the specificity of the classifier.
Original languageEnglish
Pages (from-to)44-58
Number of pages15
JournalJournal of Proteomics
Publication statusPublished - 1 Feb 2014


Cite this

Frantzi, M., Metzger, J., Banks, R. E., Husi, H., Klein, J., Dakna, M., ... Merseburger, A. S. (2014). Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. Journal of Proteomics, 98C, 44-58.